{
    "root": "35a7289a-d7c1-32cf-e063-6394a90aeebd",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Aripiprazole",
    "value": "20250521",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "ARIPIPRAZOLE",
            "code": "82VFR53I78",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31236"
        }
    ],
    "indications": {
        "text": "aripiprazole oral tablets , indicated treatment : schizophrenia acute treatment manic mixed episodes associated bipolar disorder adjunctive treatment major depressive disorder irritability associated autistic disorder treatment tourette \u2019 disorder",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "bipolar disorder (DOID:3312)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3312"
            },
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            },
            {
                "text": "autistic disorder (DOID:12849)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12849"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "initial dose recommended dose maximum dose schizophrenia \u2013 adults ( 2.1 ) 10 15 mg/day 10 15 mg/day 30 mg/day schizophrenia \u2013 adolescents ( 2.1 ) 2 mg/day 10 mg/day 30 mg/day bipolar mania \u2013 adults : monotherapy ( 2.2 ) 15 mg/day 15 mg/day 30 mg/day bipolar mania \u2013 adults : adjunct lithium valproate ( 2.2 ) 10 15 mg/day 15 mg/day 30 mg/day bipolar mania \u2013 pediatric patients : monotherapy adjunct lithium valproate ( 2.2 ) 2 mg/day 10 mg/day 30 mg/day major depressive disorder \u2013 adults : adjunct antidepressants ( 2.3 ) 2 5 mg/day 5 10 mg/day 15 mg/day irritability associated autistic disorder \u2013 pediatric patients ( 2.4 ) 2 mg/day 5 10 mg/day 15 mg/day tourette \u2019 disorder \u2013 ( 2.5 ) patients < 50 kg 2 mg/day 5 mg/day 10 mg/day patients \u2265 50 kg 2 mg/day 10 mg/day 20 mg/day \u2022 oral formulations : administer daily without regard meals ( 2 ) \u2022 known cyp2d6 poor metabolizers : half usual dose ( 2.7 )",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            },
            {
                "text": "autistic disorder (DOID:12849)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12849"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "aripiprazole tablets , usp markings one side available 20 mg , white off-white round , \u201c ari \u201d \u201c 20 \u201d ndc : 70518-2806-00 ndc : 70518-2806-01 ndc : 70518-2806-02 ndc : 70518-2806-03 packaging : 30 1 box packaging : 1 1 pouch packaging : 30 1 blister pack packaging : 30 1 blister pack store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "aripiprazole tablets contraindicated patients history hypersensitivity reaction aripiprazole . ranged pruritus/urticaria anaphylaxis [ ( 6.2 ) ] .",
    "indications_original": "Aripiprazole Oral Tablets, are indicated for the treatment of:\n                  \n                  \n                     Schizophrenia\n  \n   \u00a0\n                     \n                     Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder\n  \n   \u00a0\n                     \n                     Adjunctive Treatment of Major Depressive Disorder\n  \n   \u00a0\n                     \n                     Irritability Associated with Autistic Disorder\n  \n   \u00a0\u00a0\n                     \n                     Treatment of Tourette\u2019s Disorder",
    "contraindications_original": "Initial Dose Recommended Dose Maximum Dose Schizophrenia \u2013 adults ( 2.1 ) 10 to 15 mg/day 10 to 15 mg/day 30 mg/day Schizophrenia \u2013 adolescents ( 2.1 ) 2 mg/day 10 mg/day 30 mg/day Bipolar mania \u2013 adults: monotherapy ( 2.2 ) 15 mg/day 15 mg/day 30 mg/day Bipolar mania \u2013 adults: adjunct to lithium or valproate ( 2.2 ) 10 to\u00a015 mg/day 15 mg/day 30 mg/day Bipolar mania \u2013 pediatric patients: monotherapy or as an adjunct to lithium or valproate ( 2.2 ) 2 mg/day 10 mg/day 30 mg/day Major Depressive Disorder \u2013 adults: adjunct\u00a0 to antidepressants ( 2.3 ) 2\u00a0to\u00a05 mg/day 5 to 10 mg/day 15 mg/day Irritability associated with autistic disorder \u2013 pediatric patients ( 2.4 ) 2 mg/day 5 to 10 mg/day 15 mg/day Tourette\u2019s disorder \u2013 ( 2.5 ) Patients < 50 kg 2 mg/day 5 mg/day 10 mg/day Patients \u2265 50 kg 2 mg/day 10 mg/day 20 mg/day \u2022 Oral formulations: Administer once daily without regard to meals ( 2 ) \u2022 Known CYP2D6 poor metabolizers: Half of the usual dose ( 2.7 )",
    "warningsAndPrecautions_original": "Aripiprazole Tablets, USP\u00a0have markings on one side and are available\n                  20 mg, White to off-white round, \u201cARI\u201dand \u201c20\u201d\n                  NDC: 70518-2806-00\n                  NDC: 70518-2806-01\n                  NDC: 70518-2806-02\n                  NDC: 70518-2806-03\n                  PACKAGING: 30 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  \n                  Store at 25\u00b0C (77\u00b0F); excursions permitted between 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature].\n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Aripiprazole Tablets is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. Reactions have ranged from pruritus/urticaria to anaphylaxis\n \n  [see\u00a0Adverse Reactions\u00a0(\n  \n   6.2)].",
    "drug": [
        {
            "name": "Aripiprazole",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31236"
        }
    ]
}